Business
Cue Biopharma Announces Publication in Clinical Cancer Research of Preclinical and Translational Data Supporting the Therapeutic Potential of CUE-101 in HPV16-Related Malignancies
CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of
About this update from Cue Biopharma, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today the publication of research demonstrating the ability of its lead biologic candidate CUE-101 to activate tumor antigen specific antitumor immunity in the peer-reviewed medical journal Clinical Cancer Research, a journal of the American Association for Cancer Research. The manuscript by Steven Quayle et al. is titled “CUE-101, a Novel HPV16 E7 pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies.” (http://bit.ly/2twfkxd)\n The research highlights the ability of the company’s proprietary Immuno-STAT™ (Selective Targeting and Alternation of T cells) platform to selectively engage and modulate targeted T cells within the body. CUE-101 is the company’s lead drug candidate from the IL-2 based CUE-100 series designed to directly engage and activate T cells to target HPV16-driven recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The published results show that CUE-101 demonstrated selective binding, activation and expansion of the disease-relevant human T cell population in vitro, as well as predict a favorable safety profile. A murine surrogate molecule (mCUE-101) administered to HPV16 E7 tumor bearing mice resulted in selective expansion of disease-relevant T cells, anti-cancer efficacy and immunologic memory. In addition, mCUE-101 administered as a combination therapy with anti-PD-1 checkpoint inhibition further enhanced anti-tumor efficacy. These data support the potential for CUE-101 to enhance anti-tumor immunity in HPV16-driven malignancies. CUE-101 is currently being studied in a Phase 1 clinical trial (NCT03978689) for HPV16-driven HNSCC. The Phase 1 trial is evaluating the safety and tolerability, anti-tumor response, pharmacokinetics and immunogenicity of CUE-101 as a monotherapy in patients with confirmed HPV16-driven recurrent/metastatic HNSCC and HLA-A*02:01 serotype. Based on results from this trial, including translational pharmacodynamic immunorofiling data, the company may expand the study to test CUE-101 in the neoadjuvant setting and in combination with checkpoint inh...